Evidence map›Paper›PMID 35939083›Full record

Trial reportPsychopharmacology2022

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.

Rosalind Watts, Hannes Kettner, Dana Geerts, Sam Gandy, Laura Kartner, Lea Mertens, Christopher Timmermann, Matthew M Nour, Mendel Kaelen, David Nutt and 2 more

Open access · hybridAbstract readRandomized Controlled TrialObservational Study
In one paragraph

Trial report in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 4 pooled it
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025
    Pooled it
  5. Trial
  6. Trial
  7. Oxytocin Amplifies Negative Response to Ambiguity in Adolescent Females With and Without Eating Disorders.European eating disorders review : the journal of the Eating Disorders Association · 2025
    Trial
  8. Trial
  9. Psychedelics and the 'inner healer': Myth or mechanism?Journal of psychopharmacology (Oxford, England) · 2024
    Trial
  10. Trial
  11. Psychedelic-assisted psychotherapy: Emerging paradigm.Canadian family physician Medecin de famille canadien · 2026
    Review
  12. Canadian family physician Medecin de famille canadien · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Rosalind WattsCentre for Psychedelic Research, Imperial College London, London, UK. contact@drrosalindwatts.com.
Hannes KettnerCentre for Psychedelic Research, Imperial College London, London, UK.
Dana GeertsCentre for Psychedelic Research, Imperial College London, London, UK.
Sam GandyCentre for Psychedelic Research, Imperial College London, London, UK.
Laura KartnerCentre for Psychedelic Research, Imperial College London, London, UK.
Lea MertensCentre for Psychedelic Research, Imperial College London, London, UK.
Christopher TimmermannCentre for Psychedelic Research, Imperial College London, London, UK.
Matthew M NourCentre for Psychedelic Research, Imperial College London, London, UK.
Mendel KaelenCentre for Psychedelic Research, Imperial College London, London, UK.
David NuttCentre for Psychedelic Research, Imperial College London, London, UK.
Robin Carhart-HarrisCentre for Psychedelic Research, Imperial College London, London, UK.
Leor RosemanCentre for Psychedelic Research, Imperial College London, London, UK. Leor.roseman13@imperial.ac.uk.ORCID http://orcid.org/0000-0001-9990-6029
Imperial College London · GBKnowledge Integration (United Kingdom) · GBMaastricht University · NLNIHR Imperial Biomedical Research Centre · GBUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleA general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of 'connectedness' as 'a state of feeling connected to self, others and the wider world'. Existing tools for measuring connectedness have focused on particular aspects of connectedness, such as 'social connectedness' or 'nature connectedness', which we hypothesise to be different expressions of a common factor of connectedness. Here, we sought to develop a new scale to measure connectedness as a construct with these multiple domains. We hypothesised that (1) our scale would measure three separable subscale factors pertaining to a felt connection to 'self', 'others' and 'world' and (2) improvements in total and subscale WCS scores would correlate with improved mental health outcomes post psychedelic use.

objectivesTo validate and test the 'Watts Connectedness Scale' (WCS).

methodsPsychometric validation of the WCS was carried out using data from three independent studies. Firstly, we pooled data from two prospective observational online survey studies. The WCS was completed before and after a planned psychedelic experience. The total sample of completers from the online surveys was N = 1226. Exploratory and confirmatory factor analysis were performed, and construct and criterion validity were tested. A third dataset was derived from a double-blind randomised controlled trial (RCT) comparing psilocybin-assisted therapy (n = 27) with 6 weeks of daily escitalopram (n = 25) for major depressive disorder (MDD), where the WCS was completed at baseline and at a 6-week primary endpoint.

resultsAs hypothesised, factor analysis of all WCS items revealed three main factors with good internal consistency. WCS showed good construct validity. Significant post-psychedelic increases were observed for total connectedness scores (η2 = 0.339, p < 0.0001), as well as on each of its subscales (p < 0.0001). Acute measures of 'mystical experience', 'emotional breakthrough', and 'communitas' correlated positively with post-psychedelic changes in connectedness (r = 0.42, r = 0.38, r = 0.42, respectively, p < 0.0001). In the RCT, psilocybin therapy was associated with greater increases in WCS scores compared with the escitalopram arm (η

conclusionsThe WCS is a new 3-dimensional index of felt connectedness that may sensitively measure therapeutically relevant psychological changes post-psychedelic use. We believe that the operational definition of connectedness captured by the WCS may have broad relevance in mental health research.

Indexed as

HallucinogensMajor Depressive DisorderEmotionsHumansPsilocybinSurveys and QuestionnairesHallucinogensPsilocybinAlienationCommunityDepressionNature-connectednessPsilocybinPsychedelicsRelationalTherapyTransdiagnosticTranspersonal

Identifiers

PMID35939083
PMCPMC9358368
OpenAlexW4290631853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.